A Phase 2 Study of Trametinib for Patients With Pediatric Glioma or Plexiform Neurofibroma With Refractory Tumor and Activation of the MAPK/ERK Pathway
Latest Information Update: 28 Oct 2022
At a glance
- Drugs Trametinib (Primary)
- Indications CNS cancer; Glioma; Neurofibromatosis 1; Plexiform neurofibroma
- Focus Therapeutic Use
- Acronyms TRAM-01
- 25 Oct 2022 Planned End Date changed from 1 Dec 2026 to 1 Mar 2027.
- 25 Oct 2022 Planned primary completion date changed from 1 Jun 2026 to 1 Mar 2027.
- 25 Oct 2022 Status changed from recruiting to active, no longer recruiting.